Therapeutic potential of nitric oxide synthase inhibitor from natural sources for the treatment of ischemic stroke.
Ischemic stroke
Molecular docking
Natural sources
Nitric oxide synthase inhibitor
Journal
Saudi journal of biological sciences
ISSN: 1319-562X
Titre abrégé: Saudi J Biol Sci
Pays: Saudi Arabia
ID NLM: 101543796
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
05
09
2021
revised:
03
10
2021
accepted:
03
10
2021
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
2
2022
Statut:
ppublish
Résumé
Nitric oxide (NO) is one of the major signalling molecules in the mammalian body playing critical role in regulation of blood pressure, cardiovascular disease including stroke, immune activation, neuronal and cell communication. Moreover, hyper production of NO by the activity of nitric oxide synthase (NOS) involved in neuropathic pain, neurodegenerative disorders and stroke. Hence, the search on small molecules from the natural sources for the inhibition of NOS is desirable in therapeutic point of view. The elevated level of NO caused by NOS enzyme become a novel target in finding new inhibitors from natural sources as antistroke agents. The present study focuses on the molecular docking of quercetin and its analogues against NOS. The active site of the enzyme was docked with the ligand and pharmacological properties were analysed. From this result, we suggest the therapeutic property of quercetin and its analogues against NOS.
Identifiants
pubmed: 35197767
doi: 10.1016/j.sjbs.2021.10.003
pii: S1319-562X(21)00882-2
pmc: PMC8848027
doi:
Types de publication
Journal Article
Langues
eng
Pagination
984-991Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Neurosurgery. 2005 Dec;57(6):1272-81; discussion 1272-81
pubmed: 16331176
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
Biochem Pharmacol. 2000 Nov 15;60(10):1539-48
pubmed: 11020457
Biochim Biophys Acta. 2010 Jan;1802(1):80-91
pubmed: 19751827
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
J Neurosci. 1997 Dec 1;17(23):9157-64
pubmed: 9364062
J Immunol. 1997 May 15;158(10):4938-46
pubmed: 9144512
J Comput Aided Mol Des. 2012 Jun;26(6):787-99
pubmed: 22576241
Proteins. 2004 May 1;55(2):288-304
pubmed: 15048822
Genomics. 1994 May 15;21(2):419-22
pubmed: 7522210
Chem Res Toxicol. 1996 Jul-Aug;9(5):809-20
pubmed: 8828915
Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9
pubmed: 17184768
PLoS One. 2012;7(12):e52005
pubmed: 23300588
Cell. 1994 Sep 23;78(6):919-25
pubmed: 7923361
J Chem Theory Comput. 2016 Jan 12;12(1):281-96
pubmed: 26584231
Free Radic Biol Med. 2005 Aug 1;39(3):412-25
pubmed: 15993340
Free Radic Biol Med. 2018 Feb 1;115:395-404
pubmed: 29275014
EMBO J. 1999 Nov 15;18(22):6260-70
pubmed: 10562538
Nutr Cancer. 2007;59(2):152-62
pubmed: 18001209
Acta Physiol Scand. 2001 Sep;173(1):119-26
pubmed: 11678734
Stroke. 2002 Sep;33(9):2304-10
pubmed: 12215603
Spectrochim Acta A Mol Biomol Spectrosc. 2021 Feb 5;246:118977
pubmed: 33017787
J Med Chem. 2006 Jun 1;49(11):3315-21
pubmed: 16722650
J Med Chem. 2004 Mar 25;47(7):1750-9
pubmed: 15027866